Campos Carlos M, Suwannasom Pannipa, Koenig Wolfgang, Serruys Patrick W, Garcia-Garcia Hector M
Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Expert Rev Cardiovasc Ther. 2015 Jan;13(1):33-48. doi: 10.1586/14779072.2015.986466.
Elevated levels of phospholipase A2 have been linked to atherosclerotic plaque progression, instability via promoting inflammation and subsequent acute coronary events. Epidemiological studies have demonstrated the correlation between elevated levels associated phospholipase A2 and cardiovascular events. Therefore, specific inhibition of lipoprotein-associated phospholipase A2 with darapladib has been tested as a therapeutic option for atherosclerosis. The aim of this profile is to review the physiologic aspects of lipoprotein-associated phospholipase A2 and to revisit the clinical evidence of darapladib as therapeutic option for atherosclerosis.
磷脂酶A2水平升高与动脉粥样硬化斑块进展、通过促进炎症及随后的急性冠状动脉事件导致的不稳定性有关。流行病学研究已证实与磷脂酶A2水平升高相关的心血管事件之间的相关性。因此，已对使用达普拉地布特异性抑制脂蛋白相关磷脂酶A2作为动脉粥样硬化的一种治疗选择进行了测试。本综述的目的是回顾脂蛋白相关磷脂酶A2的生理方面，并重新审视达普拉地布作为动脉粥样硬化治疗选择的临床证据。
Zotero 插件